In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


North American Biologicals, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Announces a public offering of 4.2 mil. shares of common stock. The Miami, Florida-based provider of human blood plasma elements and plasma/sera-based diagnostic products will offer 2.7 mil. shares, and two selling shareholders will offer 1.5 mil. Assuming the company's planned selling price of $6.50 per share, NABI will gain net proceeds of approximately $15.5 mil. through its 2.7 mil. shares. Additional proceeds could be realized through the sale of 630,000 over-allotment shares by underwriters Raymond James-& Associates and NatWest Securities Limited.



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts